Trials / Withdrawn
WithdrawnNCT02856867
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN): A Randomized, Placebo-controlled, Triple-blind Phase II Study
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multicenter, randomized, placebo-controlled, triple-blind phase II trial. The randomization will be a 1:1 randomization (experimental arm:control arm). This study will enroll patients with histologically confirmed esophagogastric adenocarcinoma with metastatic disease. Patients will have had no previous chemotherapy for metastatic esophagogastric cancer. Patients will receive nintedanib or placebo in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days). Dose modification of nintedanib or placebo and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression. The primary objective is to test the hypothesis that progression free survival (PFS) is prolonged in HER2-negative patients with untreated metastatic esophagogastric adenocarcinoma when treated with nintedanib plus modified FOLFOX6 (mFOLFOX6) as compared to placebo plus mFOLFOX6. The analyses will be performed when 124 events for PFS will have been observed in the pooled arms.
Conditions
- Esophagogastric Adenocarcinoma
- Metastatic Disease
- No Previous Chemotherapy for Metastatic Esophagogastric Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | |
| DRUG | Fluorouracil | |
| DRUG | Leucovorin | |
| DRUG | Oxaliplatin | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-12-01
- Primary completion
- 2019-06-01
- First posted
- 2016-08-05
- Last updated
- 2017-05-09
Source: ClinicalTrials.gov record NCT02856867. Inclusion in this directory is not an endorsement.